

Malta, 2 May 2008  
Circular No. P08/2008

Dear Healthcare Professional,

**Re: Use of Angiotensin II Receptor Inhibitors during Pregnancy**

Following a review of all centrally authorised angiotensin II receptor antagonists<sup>1</sup>, the Committee for Medicinal Products for Human Use (CHMP) recommended that the product information for these medicines should state that the use of angiotensin II receptor antagonists should be avoided during the first trimester of pregnancy. The Medicines Authority has participated in these discussions held at the European Medicines Agency (EMA) and is in agreement with the [press release](#) and [Q&A document](#) issued by the EMA, attached here for your perusal.

---

<sup>1</sup> Irbesartan, telmisartan and valsartan